SELLAS Life Sciences Group, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for the quarter ending 2016-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for the quarter ending 2016-06-30 was $247.00K.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for fiscal 2016 was $261.00K, a 741.94% increase from fiscal 2015.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for fiscal 2015 was $31.00K, a 99.29% decline from fiscal 2014.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for fiscal 2014 was $4.34M, a 665.78% increase from fiscal 2013.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, stock options exercised for fiscal 2013 was $567.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | $247.00K derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $261.00K 10-K · filed 2017-03-15 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $261.00K derived: sum of 4 quarters · filed 2017-03-15 |
| 2016-06-30 | $247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $291.00K derived: sum of 4 quarters · filed 2017-03-15 |
| 2016-03-31 | $14.00K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $31.00K 10-K · filed 2017-03-15 |
| 2015-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $4.34M 10-K · filed 2017-03-15 |
| 2014-09-30 | $272.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $4.90M derived: sum of 4 quarters · filed 2016-04-15 |
| 2014-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | |
| 2014-03-31 | $4.06M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $558.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2016-04-15 | $567.00K 10-K/A · filed 2016-04-15 |
| 2012-12-31 | $21.00K 8-K · filed 2015-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |